Pyxis Oncology Catalysts on Track With Upcoming Trial Results in Head, Neck Cancer Treatment, RBC Says

11:33 AM EST, 11/06/2026 (MT Newswires) -- Pyxis Oncology (PYXS) catalysts are on track with the anticipated Q4 results of the combination of micvotabart pelidotin, or MICVO, and pembrolizumab in head and neck squamous cell carcinoma and second-line overall survival in H1 of 2027, RBC Capital Markets said in a Friday note. The upcoming results are likely to provide additional evidence of MICVO as an active drug in treating the disease and could potentially inflect the stock, RBC analysts said. Feedback on dose selection from the US Food and Drug Administration is expected in Q1 of 2027, and the Headliner trial, a pivotal phase 3 study, remains on track to start in mid-2027, with the analysts modeling a 65% probability of success, according to the note. The analysts said there was a substantial opportunity of around $1 billion in US sales by 2035 in the second-line treatment market for head and neck cancer. RBC maintained an outperform, speculative risk rating on the stock and raised the price target to $7 from $6. Price: 1.68, Change: +0.07, Percent Change: +4.35